Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
5.90
+0.16 (2.79%)
At close: Oct 3, 2025, 4:00 PM EDT
5.90
0.00 (0.00%)
Pre-market: Oct 6, 2025, 5:30 AM EDT
Solid Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
100
Market Cap
459.43M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 8.09M | -5.53M | -40.57% |
Dec 31, 2021 | 13.62M | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
SLDB News
- 4 days ago - Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 days ago - Solid Biosciences to Present at Upcoming Scientific Meetings - GlobeNewsWire
- 10 days ago - Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting - GlobeNewsWire
- 12 days ago - Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101 - GlobeNewsWire
- 12 days ago - Kinea Bio Secures $1.1M Jain Foundation Investment and Solid Biosciences Capsid License to Advance Novel Gene Therapy for Dysferlinopathy, a Rare Neuromuscular Disease - Business Wire
- 4 weeks ago - Solid Biosciences Inc. (SLDB) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 5 weeks ago - Solid Biosciences to Participate at Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire